Send to

Choose Destination
See comment in PubMed Commons below
Eur J Heart Fail. 2003 Oct;5(5):669-77.

Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure.

Author information

Kyoto University Graduate School of Medicine, 54 Kawahara-cho Shogoin, Sakyo-ku, Kyoto 606-8507, Japan.

Erratum in

  • Eur J Heart Fail. 2004 Jun;6(4):523.



Candesartan cilexetil is a new angiotensin II receptor blocker with a high affinity for the angiotensin II-subtype 1 receptor.


This 6-month study examined the safety and efficacy of candesartan cilexetil, 8 mg once daily, to prevent the progression of congestive heart failure (CHF).


This randomised, double-blind, placebo-controlled study enrolled 305 patients with CHF who were not receiving ACE inhibitor therapy. The composite primary efficacy endpoint was progression of CHF or addition or dose escalation of CHF medications. The secondary endpoints were incidence of cardiovascular events and changes in left ventricular function.


The study was prematurely terminated after the second interim safety analysis. The incidence of confirmed progression of CHF was significantly lower in the candesartan group (7.4%) than in the placebo group (22.2%), with a risk reduction of 66.7% and a risk difference of -14.8% (95% CI: -22.8 to -6.8%, P<0.001). Cardiovascular events were also significantly lower during treatment with candesartan than with placebo (10.8% vs. 22.9%) with a risk reduction of 52.8% and a risk difference of -12.1% (95% CI: -20.6 to -3.6%, P<0.01). The actively treated group had a significant improvement in hemodynamics. Candesartan cilexetil was well tolerated.


Candesartan cilexetil, 8 mg/day, significantly reduced the progression of CHF when compared with placebo.

[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center